ArticleCureus2025
Characteristics and Outcome of Children and Adolescents Diagnosed With Ewing Sarcoma Treated at a Tertiary Cancer Center in India: A Single-Institution Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEwing sarcoma (ES) is a malignant, aggressive tumor most frequently diagnosed among pediatric and adolescent populations. Patients with ES in low-middle income countries (LMIC) have dismal outcomes. The aim of this study is to evaluate the outcomes in children and adolescents with ES treated using a multimodal uniform treatment protocol.
methodsA retrospective analysis was conducted on 54 children and adolescents <18 years of age diagnosed with ES who received treatment from January 2021 to December 2022 at a tertiary cancer center in Western India. Data were retrieved from the hospital database, including clinical and medical records.
resultsThe study included 32 males (59%) and 22 females (41%) with a male-to-female ratio of 1.45:1. The median age of presentation was 13 years (ranging from four to 17 years). Localized disease was observed in 36 patients (67%) and metastatic disease in 18 patients (33%). Extremities were the most common primary sites (35 patients, 65%). Among the patients, 15 (28%) achieved complete response (CR), seven (13%) had persistent disease, 25 (46%) had incomplete response, and seven (13%) experienced disease progression on chemotherapy. The median (IQR) OS was 36 months (30-42 months), with three-year overall survival (OS) and progression-free survival (PFS) rates of 55% and 40%, respectively.
conclusionIn ES, complete resection of tumors with negative margins (i.e., R0 resection) significantly improves outcomes when combined with chemotherapy and radiotherapy. Survival is greatly increased upon achieving CR, highlighting the significance of successful early therapy. For this patient population to have better outcomes, further research and closing disparities in healthcare in LMICs are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.